The first Fortune Innovation Forum was successfully held in Hong Kong from March 27th to 28th, bringing together experts, investors, and leaders from leading global companies to share unique insights on reshaping the global economic power. At the meeting, the highly anticipated first Fortune Asia Future 30 list was announced, and Imeik was successfully selected with its strong research and development capabilities, rich product pipeline, and excellent growth potential, becoming one of the representative enterprises showcasing the vitality of the Asia Pacific region.
Against the backdrop of intensified geopolitical conflicts, ongoing energy crises, and uncertain macroeconomic environment, various regions around the world are actively seeking new opportunities to overcome risks and challenges and promote sustainable economic growth. The Fortune Conference has always been recognized as one of the most influential business gatherings globally. Since its launch in 1995, it has been held in more than 20 different cities around the world, bringing together elites from various fields to jointly solve complex global problems. This year, the first Fortune Innovation Forum focuses on Asia, one of the most economically active regions in the world, exploring important topics such as climate crisis and energy transition, global talent competition, financial industry transformation, artificial intelligence and digitization.
Innovation capability is the moat of a company's long-term capital value. In recent years, Aimaike has continuously increased its research and development innovation, and strengthened its strategic layout in multiple fields. The company has a rich pipeline in the future, covering multiple aspects such as medical devices, biopharmaceuticals, and chemical drugs, targeting multiple application scenarios such as skin anti-aging management, weight management, and postoperative repair. Aimaike is committed to creating multi-dimensional joint treatment solutions, building a brand moat with diversified strategies, and nurturing long-term vitality through the development of new product categories. Being selected for the Fortune Asia Future 30 also demonstrates the innovative and managerial abilities that Aimaike possesses when facing uncertain challenges in the future.
From the perspective of business performance, the company's performance has steadily increased. In the recently released 2023 annual report, the company achieved a revenue of 2.869 billion yuan and a net profit attributable to the parent company of 1.858 billion yuan, both of which increased significantly by nearly 50% year-on-year; The net cash flow generated from operating activities was 1.954 billion yuan, a year-on-year increase of 63.67%.
As China becomes the world's second-largest medical beauty market, consumers are increasingly inclined to incorporate medical beauty into their daily lives. Everyone has the right to pursue beauty, and the field of light medical beauty contains tremendous vitality and development potential.
Looking ahead to the future, Aimaike will maintain growth vitality, activate innovation potential, and jointly shape new driving forces for industry and regional economic development with strong research and development capabilities, rich product reserves, and sustainable strategic deployment.
